Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - Aug 29, 2026 - Abstract #P3561; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."
Clinical • Ankylosing Spondylitis • Axial Spondyloarthritis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP
|
|
Kevin Martz DO 1; M. Anthony Sofia MD 2
|